Semaglutide (Ozempic, Wegovy): The Fullness Signal, Extended

The short version

Semaglutide — the active ingredient in the products sold as Ozempic, Wegovy and Rybelsus — copies a hormone the gut releases after a meal. That hormone, GLP-1, prompts the pancreas to release insulin when blood sugar is high, tells the stomach to empty more slowly, and signals the brain that eating can stop. The natural version is destroyed by an enzyme within minutes of appearing.

Semaglutide is engineered to survive that enzyme and to cling to a protein in the blood that keeps it in circulation, so one weekly injection sustains the fullness signal instead of letting it fade between meals.

Most of its effect on body weight happens in the brain rather than in the stomach. Rodent work shows it reaching appetite centres in the hypothalamus and brainstem, where it lowered food intake and changed which foods animals preferred — without reducing the amount of energy the body burned ^[6].

It is an approved prescription medicine for several conditions and has the largest trial record on this site. It also has the longest list of side effects, most of them digestive, and most of them arriving early.

What it is

Class. Glucagon-like peptide-1 (GLP-1) receptor agonist — an incretin mimetic, meaning it imitates a gut hormone released in response to eating.

Structure. A 31-amino-acid acylated analogue of human GLP-1. Three modifications define it. At position 8, alanine is replaced with alpha-aminoisobutyric acid, which blocks cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that clears the native hormone. At position 34, lysine is replaced with arginine. The remaining lysine at position 26 carries a C18 fatty di-acid side chain on a glutamic-acid spacer; that lipid tail binds reversibly but strongly to serum albumin, shielding the peptide from renal clearance and metabolism. The albumin tether, not the peptide sequence, is what makes once-weekly administration possible.

Regulatory status. Approved by the FDA across multiple indications and formulations: type 2 diabetes mellitus, chronic weight management, reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, in 2025, metabolic dysfunction-associated steatohepatitis. Studied and marketed as a once-weekly subcutaneous injection and a once-daily oral tablet. GLP-1 receptor agonists are not specifically prohibited by WADA as of this revision, though athletes are expected to verify current status independently.

Brand names. The compound reaches patients under several brand names, including Ozempic, Wegovy and Rybelsus, which differ in formulation and in approved indication rather than in the molecule they deliver. Published trials are reported under the compound name, which is why every result below is attributed to semaglutide rather than to a brand.

Compounded and non-pharmaceutical material sits outside the approved-product evidence base entirely. Everything summarised below was measured on the manufactured product under trial conditions.

How it works: the satiety arm

Semaglutide acts at several stations of the appetite pathway at once, and the weight effect is dominated by the ones inside the skull.

Pancreas. At beta-cell GLP-1 receptors it potentiates insulin secretion in a glucose-dependent way — the effect scales with blood sugar rather than firing regardless of it. At alpha-cell receptors it suppresses inappropriate glucagon release. This pair explains the glycaemic effect but not the weight effect.

Stomach and vagus. GLP-1 receptor activity on gastric smooth muscle and vagal afferents slows gastric emptying. Food remains in the stomach longer, distension persists between meals, and the sensation of having eaten enough is prolonged. The same slowing produces the class's characteristic digestive complaints, so tolerability and mechanism are not separable here ^[5].

Brainstem. Rodent mapping found semaglutide directly accessing the area postrema and the parabrachial nucleus ^[6]. These structures terminate meals — and the parabrachial nucleus also generates nausea, which is why the intended signal and the most reported adverse effect share circuitry rather than merely coinciding.

Hypothalamus. In the arcuate nucleus, semaglutide activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons. In rodents this reduced food intake and modified food preference, and it did so without lowering energy expenditure ^[6]. The consequence matters for interpretation: the weight change is an intake phenomenon, not a metabolic-rate phenomenon.

A formulation note. The oral tablet is co-formulated with an absorption enhancer and has very low oral bioavailability, so it is administered fasted, with minimal water, and separated from other food, drink and oral medication. This is a pharmacology constraint rather than a toxicity, but administration error reduces the absorbed dose substantially.

What the research shows

Weight management — STEP 1. In 1,961 adults with overweight or obesity and without diabetes, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline at week 68, against -2.4% with placebo — a treatment difference of roughly 12.4 percentage points ^[4]. This trial established the weight-management indication and remains the anchor figure for the compound.

Central mechanism — rodent mapping. Semaglutide lowered body weight in mice and rats through distributed central nervous system pathways, reaching the brainstem, area postrema, hypothalamic arcuate nucleus and parabrachial nucleus, reducing intake and modulating food preference with no decrease in energy expenditure ^[6]. This is the mechanistic backbone of the satiety account, and it is animal evidence.

Cardiovascular outcomes — SELECT. In 17,604 adults with pre-existing cardiovascular disease and overweight or obesity but no diabetes, once-weekly semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke against placebo (HR 0.80; 95% CI 0.72-0.90; P<0.001) — a 20% relative risk reduction ^[3].

Cardiovascular outcomes in diabetes — SUSTAIN-6. In 3,297 adults with type 2 diabetes at high cardiovascular risk, once-weekly semaglutide reduced the same composite (HR 0.74; 95% CI 0.58-0.95). The same trial recorded significantly more diabetic-retinopathy complications (HR 1.76; 95% CI 1.11-2.78) ^[7].

Kidney outcomes — FLOW. In 3,533 adults with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1.0 mg reduced major kidney-disease events — kidney failure, a 50% or greater decline in eGFR, or kidney or cardiovascular death — against placebo (HR 0.76; 95% CI 0.66-0.88) ^[2].

Head to head — SURMOUNT-5. In 751 adults with obesity, the dual GIP/GLP-1 agonist tirzepatide produced greater mean weight loss than semaglutide at 72 weeks: -20.2% against -13.7%, a difference of about 6.5 percentage points (P<0.001) ^[1]. Semaglutide opened this therapeutic category and has since been surpassed within it.

Safety synthesis. A dedicated review concluded an overall favourable risk-benefit profile in type 2 diabetes, with predominantly mild-to-moderate transient gastrointestinal effects, an increased risk of biliary disease, and pancreatic and thyroid-cancer signals for which definitive conclusions cannot yet be drawn given low incidence ^[5].

Reported effects, cautions, and what to watch

Community reports. What follows is drawn from patient and research-use community discussion. It is anecdotal, not clinical evidence, it carries no doses, and it describes what people notice rather than what a protocol measured.

The most frequently described benefit is that the constant background chatter about food goes quiet, often within the first weeks: fullness arrives sooner, portions shrink sharply, and the next meal stops occupying attention. Sugar and sweet cravings are repeatedly described as dropping away, with fried and high-fat food losing its appeal or turning faintly off-putting. Weight loss is reported by the large majority and is usually attributed to eating much less rather than to any change in activity. Among people using it for type 2 diabetes, markedly improved blood-sugar readings are a common theme, and a recurring secondary observation is that the desire to drink alcohol fades along with food cravings.

On the adverse side, nausea is the single most reported effect, peaking in the first weeks and after each increase, sometimes with vomiting, and flaring after large or fatty meals. Foul sulfur-smelling burps are a distinctive and frequent complaint, often with bloating and a sense of food sitting too long. Bowel habits are commonly disrupted in both directions. Reflux, tiredness in the day or two after an injection, headaches, lightheadedness and mild injection-site reactions all appear regularly. Some describe active food aversions, a metallic taste and heightened sensitivity to smells; a few report appetite suppressed so far that eating enough takes deliberate effort. A smaller group notes hair shedding and a more hollow face several months in, both usually attributed to the speed of weight loss rather than to the drug itself.

Cautions from the literature. Gastrointestinal intolerance dominates the adverse-effect profile in trials and is the leading cause of discontinuation, concentrated around dose escalation; nausea was reported in roughly one-third of patients ^[5]. A boxed warning covers medullary thyroid carcinoma and multiple endocrine neoplasia type 2 on the strength of rodent C-cell tumours at supratherapeutic exposure; a clear human signal has not been established, but personal or family history is treated as a contraindication ^[5]. Acute pancreatitis is a class warning and treatment is conventionally stopped if it is suspected ^[5]. Biliary disease including gallstones is increased, attributed largely to the rate and magnitude of weight loss ^[5]. In pre-existing diabetic retinopathy undergoing rapid glycaemic correction, retinopathy complications were significantly more frequent (HR 1.76; 95% CI 1.11-2.78), interpreted as early worsening driven by the speed of correction rather than retinal toxicity ^[7]. Body-composition substudies report that part of the weight lost is lean mass, raising a sarcopenia concern in older adults. Discontinuation is followed by substantial weight regain with cardiometabolic improvements reverting toward baseline, which frames this as chronic rather than curative therapy. Pregnancy is a contraindication under approved labelling, and because the molecule persists for weeks after a final dose, label guidance advises stopping well in advance of a planned pregnancy.

Where it sits in the satiety picture

Semaglutide is the reference case for the whole category. It engages a single incretin receptor, and it demonstrated that sustained occupancy of one appetite signal is enough to move body weight substantially in a randomised trial ^[4] and to change hard cardiovascular and kidney outcomes in populations at risk ^[3][2].

It also marks the boundaries of the satiety account. A single arm has since been outperformed by a dual agonist in direct comparison ^[1], and by a triple agonist in separate Phase 2 work — so appetite suppression alone is evidently not the ceiling. And because its effect runs through intake rather than expenditure ^[6], the effect is contingent on continued signalling: when the signal stops, the appetite it was suppressing returns.

Read against retatrutide, semaglutide is the narrower, better-documented instrument. Read against AOD-9604, it is the proof of the site's central claim — that in human trials, the compounds that move weight are the ones that reach the brain.